Outcomes of treat & extend ranibizumab in diabetic macular oedema
1 October 2021
| Ed Rule
|
Retina / Uvea / Vitreous
|
Diabetic macular edema, Outcome predictor, Ranibizumab, Spectral-domain optical coherence tomography, Treat and extend
This study retrospectively evaluated 118 eyes of 87 patients who received ranibizumab in a treat and extend regimen for diabetic macular oedema (DMO). Data were collected for patients under follow-up for 24 months. After 24 months, patients gained a mean...